Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

Dan Liu, Lin Shen, Jian Huang et al.|BMC Medicine|2022

Cited by 84